AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAGâ€™s chief executive officer, will participate in the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 2:00 pm Eastern Time. The presentation will include a company overview and business update, followed by a question and answer session with investors.
A live webcast of the presentation will be accessible through the Investors section of the companyâ€™s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until March 13, 2013.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that manufactures and markets FerahemeÂ® (ferumoxytol) Injection for Intravenous (IV) use in the United States. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the companyâ€™s commercial footprint and focus on hematology and oncology centers and hospital infusion centers. For additional company information, please visit www.amagpharma.com.Business Wire
Last updated on: 08/02/2013